SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE)--Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.
Vaxart to Present at ASM Microbe 2018
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться